# Coya Therapeutics, Inc.: financial statements, quarterly

COYA · Nasdaq · CIK 1835022 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coya.md) · [Financials](/companies/coya/financials.md) · [Filings](/companies/coya/filings.md) · [Insiders](/companies/coya/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coya/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0000950170-24-121837.md) | [6,002 d](/filings/0000950170-25-040782.md) | [127](/filings/0000950170-25-069824.md) | [3,425](/filings/0000950170-25-106934.md) | [0.0](/filings/0000950170-24-121837.md) | [2.0 d](/filings/0001193125-26-107281.md) | [258](/filings/0001193125-26-218201.md) | [164](/filings/0001193125-26-343481.md) | [3,564](/filings/0001193125-25-276058.md) | [3,960 d](/filings/0001193125-26-107281.md) | [251](/filings/0001193125-26-218201.md) | [244](/filings/0001193125-26-343481.md) |
| Operating income | $k | [(3,564)](/filings/0000950170-24-121837.md) | [1,815 d](/filings/0000950170-25-040782.md) | [(5,483)](/filings/0000950170-25-069824.md) | [(3,236)](/filings/0000950170-25-106934.md) | [(4,450)](/filings/0001193125-25-276058.md) | [(4,080) d](/filings/0001193125-26-107281.md) | [(7,677)](/filings/0001193125-26-218201.md) | [(6,415)](/filings/0001193125-26-343481.md) | [(2,433)](/filings/0001193125-25-276058.md) | [(6,031) d](/filings/0001193125-26-107281.md) | [(7,640)](/filings/0001193125-26-218201.md) | [(7,047)](/filings/0001193125-26-343481.md) |
| Income tax | $k | not reported | not reported | not reported | [0.0](/filings/0000950170-25-106934.md) | not reported | not reported | not reported | [0.0](/filings/0000950170-25-106934.md) | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,422)](/filings/0000950170-24-121837.md) | [1,266 d](/filings/0000950170-25-040782.md) | [(5,052)](/filings/0001193125-25-276058.md) | [(2,892)](/filings/0001193125-25-276058.md) | [(4,021)](/filings/0001193125-25-276058.md) | [(2,916) d](/filings/0001193125-26-107281.md) | [(7,307)](/filings/0001193125-26-343481.md) | [(6,095)](/filings/0001193125-26-343481.md) | [(2,116)](/filings/0001193125-25-276058.md) | [(5,709) d](/filings/0001193125-26-107281.md) | [(7,207)](/filings/0001193125-26-343481.md) | [(6,638)](/filings/0001193125-26-343481.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0000950170-24-121837.md) | not reported | [(0.35)](/filings/0000950170-25-069824.md) | [(0.19)](/filings/0000950170-25-106934.md) | [(0.26)](/filings/0001193125-25-276058.md) | not reported | [(0.44)](/filings/0001193125-26-218201.md) | [(0.36)](/filings/0001193125-26-343481.md) | [(0.13)](/filings/0001193125-25-276058.md) | not reported | [(0.32)](/filings/0001193125-26-218201.md) | [(0.28)](/filings/0001193125-26-343481.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0000950170-24-121837.md) | not reported | [(0.35)](/filings/0000950170-25-069824.md) | [(0.19)](/filings/0000950170-25-106934.md) | [(0.26)](/filings/0001193125-25-276058.md) | not reported | [(0.44)](/filings/0001193125-26-218201.md) | [(0.36)](/filings/0001193125-26-343481.md) | [(0.13)](/filings/0001193125-25-276058.md) | not reported | [(0.32)](/filings/0001193125-26-218201.md) | [(0.28)](/filings/0001193125-26-343481.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.9](/filings/0000950170-23-060718.md) | [32.6](/filings/0000950170-25-040782.md) | [36.0](/filings/0000950170-24-057056.md) | [36.6](/filings/0000950170-24-095075.md) | [31.1](/filings/0000950170-24-121837.md) | [38.3](/filings/0001193125-26-107281.md) | [35.5](/filings/0000950170-25-069824.md) | [29.8](/filings/0000950170-25-106934.md) | [28.1](/filings/0001193125-25-276058.md) | [46.8](/filings/0001193125-26-343481.md) | [50.7](/filings/0001193125-26-218201.md) | [43.2](/filings/0001193125-26-343481.md) |
| Current assets | $m | [11.8](/filings/0000950170-23-060718.md) | [41.2](/filings/0000950170-25-040782.md) | [37.3](/filings/0000950170-24-057056.md) | [39.9](/filings/0000950170-24-095075.md) | [35.5](/filings/0000950170-24-121837.md) | [44.3](/filings/0001193125-26-107281.md) | [38.4](/filings/0000950170-25-069824.md) | [33.4](/filings/0000950170-25-106934.md) | [32.0](/filings/0001193125-25-276058.md) | [49.9](/filings/0001193125-26-343481.md) | [53.3](/filings/0001193125-26-218201.md) | [47.1](/filings/0001193125-26-343481.md) |
| Total assets | $m | [11.9](/filings/0000950170-23-060718.md) | [41.3](/filings/0000950170-25-040782.md) | [37.4](/filings/0000950170-24-057056.md) | [39.9](/filings/0000950170-24-095075.md) | [35.6](/filings/0000950170-24-121837.md) | [44.3](/filings/0001193125-26-107281.md) | [38.4](/filings/0000950170-25-069824.md) | [33.5](/filings/0000950170-25-106934.md) | [32.0](/filings/0001193125-25-276058.md) | [50.0](/filings/0001193125-26-343481.md) | [53.3](/filings/0001193125-26-218201.md) | [47.3](/filings/0001193125-26-343481.md) |
| Current liabilities | $m | [1.8](/filings/0000950170-23-060718.md) | [5.1](/filings/0000950170-25-040782.md) | [4.3](/filings/0000950170-24-057056.md) | [3.8](/filings/0000950170-24-095075.md) | [2.3](/filings/0000950170-24-121837.md) | [3.8](/filings/0001193125-26-107281.md) | [4.3](/filings/0000950170-25-069824.md) | [4.5](/filings/0000950170-25-106934.md) | [3.7](/filings/0001193125-25-276058.md) | [5.9](/filings/0001193125-26-343481.md) | [3.5](/filings/0001193125-26-218201.md) | [3.5](/filings/0001193125-26-343481.md) |
| Total liabilities | $m | [1.8](/filings/0000950170-23-060718.md) | [5.6](/filings/0000950170-25-040782.md) | [5.0](/filings/0000950170-24-057056.md) | [4.7](/filings/0000950170-24-095075.md) | [3.5](/filings/0000950170-24-121837.md) | [4.8](/filings/0001193125-26-107281.md) | [5.0](/filings/0000950170-25-069824.md) | [5.1](/filings/0000950170-25-106934.md) | [4.8](/filings/0001193125-25-276058.md) | [6.9](/filings/0001193125-26-343481.md) | [4.3](/filings/0001193125-26-218201.md) | [4.0](/filings/0001193125-26-343481.md) |
| Shareholders' equity | $m | [10.1](/filings/0000950170-24-121837.md) | [35.6](/filings/0001193125-26-107281.md) | [32.4](/filings/0001193125-25-276058.md) | [35.3](/filings/0001193125-25-276058.md) | [32.0](/filings/0001193125-25-276058.md) | [39.6](/filings/0001193125-26-343481.md) | [33.4](/filings/0001193125-26-343481.md) | [28.3](/filings/0001193125-26-343481.md) | [27.3](/filings/0001193125-25-276058.md) | [43.0](/filings/0001193125-26-343481.md) | [49.0](/filings/0001193125-26-343481.md) | [43.3](/filings/0001193125-26-343481.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,216) d](/filings/0000950170-24-121837.md) | [(2,241) d](/filings/0000950170-25-040782.md) | [2,146](/filings/0000950170-25-069824.md) | [(4,564) d](/filings/0000950170-25-106934.md) | [(5,461) d](/filings/0001193125-25-276058.md) | [(2,410) d](/filings/0001193125-26-107281.md) | [(2,828)](/filings/0001193125-26-218201.md) | [(5,773) d](/filings/0001193125-26-343481.md) | [(1,131) d](/filings/0001193125-25-276058.md) | [(1,007) d](/filings/0001193125-26-107281.md) | [(6,209)](/filings/0001193125-26-218201.md) | [(7,376) d](/filings/0001193125-26-343481.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.6](/filings/0000950170-23-060718.md) | [9.7](/filings/0000950170-24-057056.md) | [9.9](/filings/0000950170-24-095075.md) | [9.9](/filings/0000950170-24-121837.md) | [14.5](/filings/0000950170-25-069824.md) | [14.9](/filings/0000950170-25-106934.md) | [15.2](/filings/0001193125-25-276058.md) | [16.7](/filings/0001193125-26-218201.md) | [16.7](/filings/0001193125-26-343481.md) | [16.7](/filings/0001193125-25-276058.md) | [22.6](/filings/0001193125-26-218201.md) | [23.5](/filings/0001193125-26-343481.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,457,849 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343481.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.